The UK-based oncology company Iksuda Therapeutics Ltd has completed a $47 million financing round to progress a pipeline of antibody-drug conjugates (ADCs), a drug class that is seeing renewed interest from investors because of advances in conjugation technologies. The financing was co-led by the South Korean entities Mirae Asset Financial Group and Celltrion Inc.
